TY - JOUR AU - Maxwell, I. F. AU - Maxwell, F. AU - Glode, L. M. PY - 1986 DA - 1986// TI - Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. JO - Cancer Res VL - 46 ID - Maxwell1986 ER - TY - JOUR AU - Peng, K. W. PY - 1999 DA - 1999// TI - Strategies for targeting therapeutic gene delivery. JO - Mol Med Today VL - 5 UR - https://doi.org/10.1016/S1357-4310(99)01579-8 DO - 10.1016/S1357-4310(99)01579-8 ID - Peng1999 ER - TY - JOUR AU - Harris, J. D. AU - Gutierrez, A. A. AU - Hurst, H. C. AU - Sikora, K. AU - Lemoine, N. R. PY - 1994 DA - 1994// TI - Gene therapy for cancer using tumour-specific prodrug activation. JO - Gene Ther VL - 1 ID - Harris1994 ER - TY - JOUR AU - Reid, R. AU - Mar, E. C. AU - Huang, E. S. AU - Topal, M. D. PY - 1988 DA - 1988// TI - Insertion and extension of acyclic, dideoxy and ara nucleotides by herpesviridae, human α and β polymerases. A unique inhibition mechanism for 9-(1, 3-dihydroxy-2-propoxymethyl) guanine triphosphate. JO - J Biol Chem VL - 263 ID - Reid1988 ER - TY - JOUR AU - Mar, E. C. AU - Chiou, J. F. AU - Huang, E. S. AU - Topal, M. D. PY - 1985 DA - 1985// TI - Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA poly-merase by triphosphates of 9-(2-hydroxyethoxymethyl) guanine and 9-(1, 3-dihydroxy-2-propoxymethyl) guanine. JO - J Virol VL - 53 ID - Mar1985 ER - TY - JOUR AU - Wallace, H. AU - Clarke, A. R. AU - Harrison, D. J. AU - Hooper, M. L. AU - Bishop, J. O. PY - 1996 DA - 1996// TI - Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apopto-sis. JO - Oncogene VL - 13 ID - Wallace1996 ER - TY - JOUR AU - Kokoris, M. AU - Sabo, P. AU - Adman, E. AU - Black, M. PY - 1999 DA - 1999// TI - Enhancement of tumourablation by a selected HSV-1 thymidine kinase mutant. JO - Gene Ther VL - 6 UR - https://doi.org/10.1038/sj.gt.3300966 DO - 10.1038/sj.gt.3300966 ID - Kokoris1999 ER - TY - JOUR AU - Pinedo, H. M. AU - Peters, G. F. J. PY - 1988 DA - 1988// TI - Fluorouracil: biochemistry and pharmacology. JO - J Clin Oncol VL - 6 UR - https://doi.org/10.1200/JCO.1988.6.10.1653 DO - 10.1200/JCO.1988.6.10.1653 ID - Pinedo1988 ER - TY - JOUR AU - Van der Wilt, C. L. AU - Pinedo, H. M. AU - Smid, K. PY - 1992 DA - 1992// TI - Effect of folinic acid on fluorouracil activity and expression of thymidine synthase. JO - Semin Oncol VL - 19 ID - Van der Wilt1992 ER - TY - JOUR AU - Knox, R. J. AU - Friedlos, F. AU - Boland, M. P. PY - 1993 DA - 1993// TI - The bioactivation of CB 1954 and its use as a prodrug in antiboby direct enzyme prodrug therapy (ADEPT). JO - Cancer Metastasis Rev VL - 12 UR - https://doi.org/10.1007/BF00689810 DO - 10.1007/BF00689810 ID - Knox1993 ER - TY - JOUR AU - Clark, A. J. AU - Iwobi, M. AU - Cui, W. PY - 1997 DA - 1997// TI - Selective cell ablation in transgenic mice expressing E. colinitroreductase. JO - Gene Ther VL - 4 UR - https://doi.org/10.1038/sj.gt.3300367 DO - 10.1038/sj.gt.3300367 ID - Clark1997 ER - TY - JOUR AU - Cortes, M. L. AU - de Felipe, P. AU - Martin, V. AU - Hughes, M. A. AU - Izquierdo, M. PY - 1998 DA - 1998// TI - Successful use of a plant gene in the treatment of cancer in vivo. JO - Gene Ther VL - 5 UR - https://doi.org/10.1038/sj.gt.3300751 DO - 10.1038/sj.gt.3300751 ID - Cortes1998 ER - TY - JOUR AU - Culver, K. W. AU - Ram, Z. AU - Wallbridge, S. PY - 1992 DA - 1992// TI - In vivogene transfer with retroviral vector-producer cells for treatment of experimental brain tumours. JO - Science VL - 256 UR - https://doi.org/10.1126/science.1317968 DO - 10.1126/science.1317968 ID - Culver1992 ER - TY - JOUR AU - Moolten, F. S. AU - Wells, J. M. AU - Mroz, P. J. PY - 1992 DA - 1992// TI - Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. JO - Cancer Lett VL - 64 UR - https://doi.org/10.1016/0304-3835(92)90051-V DO - 10.1016/0304-3835(92)90051-V ID - Moolten1992 ER - TY - JOUR AU - Bi, W. L. AU - Parysek, L. M. AU - Warnick, R. AU - Stambrook, P. J. PY - 1993 DA - 1993// TI - In vivoevidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. JO - Hum Gene Ther VL - 4 UR - https://doi.org/10.1089/hum.1993.4.6-725 DO - 10.1089/hum.1993.4.6-725 ID - Bi1993 ER - TY - JOUR AU - Freeman, S. AU - Abboud, C. N. AU - Whartenby, K. A. PY - 1993 DA - 1993// TI - The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. JO - Cancer Res VL - 53 ID - Freeman1993 ER - TY - JOUR AU - Kuriyama, S. AU - Masui, K. AU - Sakamoto, T. PY - 1998 DA - 1998// TI - Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitrois substantially mediated by generated 5-fluorouracil. JO - Anticancer Res VL - 18 ID - Kuriyama1998 ER - TY - JOUR AU - Bridgewater, J. A. AU - Knox, R. J. AU - Pitts, J. D. AU - Collins, M. K. AU - Springer, C. J. PY - 1997 DA - 1997// TI - The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. JO - Hum Gene Ther VL - 10 UR - https://doi.org/10.1089/hum.1997.8.6-709 DO - 10.1089/hum.1997.8.6-709 ID - Bridgewater1997 ER - TY - JOUR AU - Freeman, S. M. AU - Ramesh, R. AU - Marrogi, A. J. PY - 1997 DA - 1997// TI - Immune system in suicide gene therapy. JO - Lancet VL - 349 UR - https://doi.org/10.1016/S0140-6736(97)22001-5 DO - 10.1016/S0140-6736(97)22001-5 ID - Freeman1997 ER - TY - JOUR AU - Vile, R. G. AU - Castleden, S. AU - Marshall, J. PY - 1997 DA - 1997// TI - Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. JO - Int J Cancer VL - 71 UR - https://doi.org/3.0.CO;2-D DO - 3.0.CO;2-D ID - Vile1997 ER - TY - JOUR AU - Kianmanesh, A. R. AU - Perrin, H. AU - Panis, Y. PY - 1997 DA - 1997// TI - A distant bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. JO - Hum Gene Ther VL - 8 UR - https://doi.org/10.1089/hum.1997.8.15-1807 DO - 10.1089/hum.1997.8.15-1807 ID - Kianmanesh1997 ER - TY - JOUR AU - Consalvo, M. AU - Mullen, C. A. AU - Modesti, A. PY - 1995 DA - 1995// TI - 5-fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. JO - J Immun VL - 154 ID - Consalvo1995 ER - TY - JOUR AU - Mullen, C. A. AU - Coale, M. M. AU - Lowe, R. AU - Blaese, R. M. PY - 1994 DA - 1994// TI - Tumours expressing the cytosine deaminase suicide gene can be eliminated in vivowith 5-fluorocytosine and induce protective immunity to wild type tumor. JO - Cancer Res VL - 54 ID - Mullen1994 ER - TY - JOUR AU - Columbano, A. PY - 1995 DA - 1995// TI - Cell death: current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo. JO - J Cell Biochem VL - 58 UR - https://doi.org/10.1002/jcb.240580207 DO - 10.1002/jcb.240580207 ID - Columbano1995 ER - TY - JOUR AU - Melcher, A. AU - Todryk, S. AU - Hardwick, N. PY - 1998 DA - 1998// TI - Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. JO - Nature Med VL - 4 UR - https://doi.org/10.1038/nm0598-581 DO - 10.1038/nm0598-581 ID - Melcher1998 ER - TY - JOUR AU - Dilber, M. S. AU - Abedi, M. R. AU - Bjorkstrand, B. PY - 1996 DA - 1996// TI - Suicide gene therapy for plasma cell tumors. JO - Blood VL - 88 ID - Dilber1996 ER - TY - JOUR AU - Pandha, H. S. AU - Martin, L. A. AU - Rigg, A. PY - 1999 DA - 1999// TI - Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.7.2180 DO - 10.1200/JCO.1999.17.7.2180 ID - Pandha1999 ER - TY - JOUR AU - Lovekin, C. AU - Ellis, I. O. AU - Locker, A. PY - 1991 DA - 1991// TI - c erbB-2 oncoprotein expression in primary and advanced breast cancer. JO - Br J Cancer VL - 63 UR - https://doi.org/10.1038/bjc.1991.101 DO - 10.1038/bjc.1991.101 ID - Lovekin1991 ER - TY - JOUR AU - Bos, J. L. PY - 1989 DA - 1989// TI - Ras oncogenes in human cancer: a review. JO - Cancer Res VL - 49 ID - Bos1989 ER - TY - JOUR AU - Chin, L. AU - Tam, A. AU - Pomerantz, J. PY - 1999 DA - 1999// TI - Essential role for oncogenic Ras in tumour maintenance. JO - Nature VL - 400 UR - https://doi.org/10.1038/22788 DO - 10.1038/22788 ID - Chin1999 ER - TY - JOUR AU - Downward, J. PY - 1998 DA - 1998// TI - Ras signalling and apoptosis. JO - Curr Opin Genet Dev VL - 8 UR - https://doi.org/10.1016/S0959-437X(98)80061-0 DO - 10.1016/S0959-437X(98)80061-0 ID - Downward1998 ER - TY - JOUR AU - Rodriguez-Visciana, P. AU - Warne, P. H. AU - Khwaja, A. PY - 1997 DA - 1997// TI - Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. JO - Cell VL - 89 UR - https://doi.org/10.1016/S0092-8674(00)80226-3 DO - 10.1016/S0092-8674(00)80226-3 ID - Rodriguez-Visciana1997 ER - TY - JOUR AU - Marshall, C. J. PY - 1996 DA - 1996// TI - Ras effectors. JO - Curr Opin Cell Biol VL - 8 UR - https://doi.org/10.1016/S0955-0674(96)80066-4 DO - 10.1016/S0955-0674(96)80066-4 ID - Marshall1996 ER - TY - JOUR AU - Clanton, T. J. AU - Hattori, S. AU - Shih, T. Y. PY - 1986 DA - 1986// TI - Mutations of the rasgene product p21 that abolish guanine nucleotide binding. JO - Proc Natl Acad Sci USA VL - 83 UR - https://doi.org/10.1073/pnas.83.14.5076 DO - 10.1073/pnas.83.14.5076 ID - Clanton1986 ER - TY - JOUR AU - Ogiso, Y. AU - Sakai, N. AU - Watari, H. AU - Yokohama, T. AU - Kuzumaki, N. PY - 1994 DA - 1994// TI - Suppression of various human tumor cell lines by a dominant negative H-rasmutant. JO - Gene Ther VL - 1 ID - Ogiso1994 ER - TY - JOUR AU - Senmaru, N. AU - Shichinohe, T. AU - Takeuchi, M. PY - 1998 DA - 1998// TI - Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Rasmutant, N116Y. JO - Int J Cancer VL - 78 UR - https://doi.org/3.0.CO;2-4 DO - 3.0.CO;2-4 ID - Senmaru1998 ER - TY - JOUR AU - Chen, L. AU - Chen, D. AU - Manome, Y. PY - 1995 DA - 1995// TI - Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. JO - J Clin Invest VL - 96 UR - https://doi.org/10.1172/JCI118347 DO - 10.1172/JCI118347 ID - Chen1995 ER - TY - JOUR AU - Vassaux, G. AU - Hurst, H. C. AU - Lemoine, N. R. PY - 1999 DA - 1999// TI - Insulation of a conditionally expressed transgene in an adenoviral vector. JO - Gene Ther VL - 6 UR - https://doi.org/10.1038/sj.gt.3300910 DO - 10.1038/sj.gt.3300910 ID - Vassaux1999 ER - TY - JOUR AU - Ring, C. J. A. AU - Blouin, P. AU - Martin, L. A. AU - Hurst, H. C. AU - Lemoine, N. R. PY - 1997 DA - 1997// TI - Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. JO - Gene Ther VL - 4 UR - https://doi.org/10.1038/sj.gt.3300510 DO - 10.1038/sj.gt.3300510 ID - Ring1997 ER -